Abstract:
En
|
Text:
En
|
PDF:
En
Abstract This study aimed to describe the pattern of antimicrobial agent usage in a general tertiary care hospital in Rio de Janeiro. Some prescriptions were evaluated for its therapeutic indication, dose, route of administration, and duration of treatment based on Antimicrobial Application Sheets and daily medical prescriptions. Consumption was expressed by using Defined Daily Dose per 100 bed-days. Within the 20,182 validated prescriptions, 9,356 were eligible for the study. The first-choice therapy was prescribed 6,175 (66.01%) times. It was verified that 5,455 (58.31%) of the prescribed antimicrobial agents were associated with bacteriologic culture tests, and among 2,484 (45.54%) of such cultures, at least one microorganism was identified. Negative results were obtained in 2,971 (54.46%) processed cultures, in which 1,289 patients (43.49%) had already initiated antimicrobial therapy. From patients with negative cultures, 518 (33.99%) prescriptions had alternative treatments, and from these, 495 (95.96%) could have been changed. Therefore, de-escalation of antimicrobial therapy has not been a practice in the institution. Among prescriptions that needed renal function dose adjustments, this was performed in 81.11%. In general, prescriptions were adjusted for dose (70.03%), route of administration (99.63%) and duration of treatment (74.70%). Piperacillin/tazobactam was the mostly used antimicrobial (3,923 DDD/100 bed-days). Janeiro indication 10 beddays. beddays bed days. days bed-days 20182 20 182 20,18 9356 9 356 9,35 firstchoice first choice 6175 6 175 6,17 66.01% 6601 66 01 (66.01% times 5455 5 455 5,45 58.31% 5831 58 31 (58.31% tests 2484 2 484 2,48 45.54% 4554 45 54 (45.54% cultures identified 2971 971 2,97 54.46% 5446 46 (54.46% 1289 1 289 1,28 43.49% 4349 43 49 (43.49% 51 33.99% 3399 33 99 (33.99% treatments these 95.96% 9596 95 96 (95.96% changed Therefore deescalation escalation institution adjustments 8111 81 11 81.11% 70.03%, 7003 70.03% , 70 03 (70.03%) 99.63% 9963 63 (99.63% 74.70%. 7470 74.70% . 74 (74.70%) Piperacillintazobactam Piperacillin tazobactam 3,923 3923 3 923 (3,92 DDD100 DDD DDD/10 bed-days) 2018 18 20,1 935 35 9,3 617 17 6,1 66.01 660 0 (66.01 545 5,4 58.31 583 (58.31 248 48 2,4 45.54 4 (45.54 297 97 2,9 54.46 544 (54.46 128 28 1,2 43.49 434 (43.49 33.99 339 (33.99 95.96 959 (95.96 811 8 81.11 700 70.03 7 (70.03% 99.63 996 (99.63 747 74.70 (74.70% 3,92 392 92 (3,9 DDD10 DDD/1 201 20, 93 9, 61 6, 66.0 (66.0 5, 58.3 (58.3 24 2, 45.5 (45.5 29 54.4 (54.4 12 1, 43.4 (43.4 33.9 (33.9 95.9 (95.9 81.1 70.0 (70.03 99.6 (99.6 74.7 (74.70 3,9 39 (3, DDD1 DDD/ 66. (66. 58. (58. 45. (45. 54. (54. 43. (43. 33. (33. 95. (95. 81. 70. (70.0 99. (99. 74. (74.7 3, (3 (66 (58 (45 (54 (43 (33 (95 (70. (99 (74. ( (6 (5 (4 (9 (70 (74 (7